Aura Biosciences (AURA) Income from Continuing Operations (2020 - 2026)
Aura Biosciences (AURA) reported Income from Continuing Operations of 33685000.0 for Q1 2026, down 22.56% on a YoY basis from 43496933.29 in Q1 2025, and down 31.83% quarter-over-quarter from 25552000.0 in Q4 2025.
Aura Biosciences (AURA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Aura Biosciences has reported Income from Continuing Operations for 7 years, with the latest figure at 33685000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 22.56% year-over-year to 33685000.0; the trailing twelve-month figure through Mar 2026 stood at 112386000.0 (down 19.46% YoY), and the FY2025 full-year result was 106191000.0, down 23.05% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 33685000.0, down from 25552000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 12811000.0 in Q1 2022, with the low at 33685000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 21345588.24 across 5 years, with a median of 20337000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 116.15% — and 2025, when it decreased 1.35%.
- Aura Biosciences' Income from Continuing Operations stood at 17613000.0 in 2022, then declined by 25.65% to 22131000.0 in 2023, then decreased by 13.92% to 25212000.0 in 2024, then declined by 1.35% to 25552000.0 in 2025, then sank by 31.83% to 33685000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 33685000.0 (Q1 2026), 25552000.0 (Q4 2025), and 26130000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Aura Biosciences | 412.10 Mn | 327.31 Mn | - | -33.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.69 Mn |
| Dec 31, 2025 | -25.55 Mn |
| Sep 30, 2025 | -26.13 Mn |
| Jun 30, 2025 | -27.02 Mn |
| Mar 31, 2025 | -27.49 Mn |
| Dec 31, 2024 | -25.21 Mn |
| Sep 30, 2024 | -21.04 Mn |
| Jun 30, 2024 | -20.34 Mn |
| Mar 31, 2024 | -19.71 Mn |
| Dec 31, 2023 | -22.13 Mn |
| Sep 30, 2023 | -18.51 Mn |
| Jun 30, 2023 | -18.30 Mn |
| Mar 31, 2023 | -17.47 Mn |
| Dec 31, 2022 | -17.61 Mn |
| Sep 30, 2022 | -16.06 Mn |
| Jun 30, 2022 | -13.82 Mn |
| Mar 31, 2022 | -12.81 Mn |
| Dec 31, 2021 | -11.63 Mn |
| Sep 30, 2021 | -8.90 Mn |
| Jun 30, 2021 | -8.80 Mn |